Authors :
Tooba Qamar; Ruchi Yadav; Prachi Srivastava
Volume/Issue :
Volume 8 - 2023, Issue 1 - January
Google Scholar :
https://bit.ly/3IIfn9N
Scribd :
https://bit.ly/3wCF0Fq
Abstract :
- SARS (Severe Acute Respiratory Syndrome)
virus is analogous to SARS-CoV-2. Both viruses share
the same beta corona virus genus (lineage B). One of the
crucial step for disease progression caused by novel
SARS-CoV-2 involves the entry of virus into the cell. The
virus entry inside the host cell is facilitated by the release
of spike fusion peptide that is formed by cleavage of
spike protein by the host protease. The receptor binding
domain similarity of both SARS-CoV-2, delineates that
ACE2 receptor is shared by both these viruses. In this
research we have studied the structural similarity of
COVID-19 surface glycoprotein. Protein sequence of
COVID-19 surface glycoprotein was retrieved from
NCBI database with Accession number:
YP_009724390.1. Protein BLAST was done against PDB
database to identify similar proteins. Similar proteins
were identified fromMiddle East respiratory syndromerelated coronavirus, Severe acute respiratory syndrome
coronavirus 2 (SARS),& other viruses PDB structures
were downloaded. Homology modeling of COVID-19
surface glycoprotein was done using modeller tool and
structural similarity was done using FATCAT tool.
Result shows that spike protein of COVID-19 have 99%
structural similarity with SARS spike protein with PDB
ID:6VSB_A. Further binding sites were predicted using
CASTp tool and binding sites were also compared with
SARS spike protein, result shows that both proteins have
similar binding sites. This study exemplifies structural
similarity of COVID-19 spike protein (surface
glycoprotein) with SARS virus spike protein and
therefore can be considered conducive in drug
repurposing of SARS inhibitors for COVID-19.
Keywords :
COVID-19; SARS; Structural Similarity; Drug Repurposing; Homology Modeling
- SARS (Severe Acute Respiratory Syndrome)
virus is analogous to SARS-CoV-2. Both viruses share
the same beta corona virus genus (lineage B). One of the
crucial step for disease progression caused by novel
SARS-CoV-2 involves the entry of virus into the cell. The
virus entry inside the host cell is facilitated by the release
of spike fusion peptide that is formed by cleavage of
spike protein by the host protease. The receptor binding
domain similarity of both SARS-CoV-2, delineates that
ACE2 receptor is shared by both these viruses. In this
research we have studied the structural similarity of
COVID-19 surface glycoprotein. Protein sequence of
COVID-19 surface glycoprotein was retrieved from
NCBI database with Accession number:
YP_009724390.1. Protein BLAST was done against PDB
database to identify similar proteins. Similar proteins
were identified fromMiddle East respiratory syndromerelated coronavirus, Severe acute respiratory syndrome
coronavirus 2 (SARS),& other viruses PDB structures
were downloaded. Homology modeling of COVID-19
surface glycoprotein was done using modeller tool and
structural similarity was done using FATCAT tool.
Result shows that spike protein of COVID-19 have 99%
structural similarity with SARS spike protein with PDB
ID:6VSB_A. Further binding sites were predicted using
CASTp tool and binding sites were also compared with
SARS spike protein, result shows that both proteins have
similar binding sites. This study exemplifies structural
similarity of COVID-19 spike protein (surface
glycoprotein) with SARS virus spike protein and
therefore can be considered conducive in drug
repurposing of SARS inhibitors for COVID-19.
Keywords :
COVID-19; SARS; Structural Similarity; Drug Repurposing; Homology Modeling
